TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive In Brief: Reducing Doses Cuts Cure Rate Every Time, DeVita Says; Hyperthermia Use In Cancer Being Assessed April 6, 1984
